Krsnaa Diagnostics Limited has received shareholder approval through a postal ballot for the preferential issue of up to 16.21 lakh convertible warrants to its Promoter and Promoter Group. The special resolution was passed with 92.69% votes in favour, enabling the company to proceed with the proposed capital issuance after completing the required regulatory and procedural formalities.
Krsnaa Diagnostics Wins Shareholder Approval for 16.21 Lakh Promoter Warrants
Resolution approved with 92.69% votes in favour.
Up to 16,21,000 convertible warrants cleared for Promoter and Promoter Group.
Reader Takeaway: Capital raising plan advances, but future equity conversion may increase the company's outstanding share base.
What just happened
Krsnaa Diagnostics Limited has announced the results of its postal ballot, with shareholders approving a special resolution for the preferential issue of up to 16,21,000 warrants convertible into equity shares.
The proposal received the requisite majority through remote e-voting. According to the scrutinizer's report, 1,73,06,571 votes were cast in favour against 13,64,985 votes against, translating into 92.6895% support. No invalid votes were recorded.
The voting process concluded on September 17, 2026.
Why this matters
The approval allows the company to move ahead with issuing convertible warrants to members of the Promoter and Promoter Group.
Convertible warrants provide the right to subscribe to equity shares upon conversion, subject to the applicable terms and regulatory requirements. Once converted, the warrants will increase the company's equity share capital.
The shareholder approval removes a key governance requirement for implementing the proposed preferential issue.
What changes now
The company can proceed with the next procedural and regulatory steps required for allotment of the warrants.
The warrants relate to equity shares having a face value of ₹5 each and are intended exclusively for the Promoter and Promoter Group, as outlined in the postal ballot notice dated August 13, 2026.
Risks to watch
Investors should monitor:
- Completion of the warrant allotment process.
- Future conversion of warrants into equity shares.
- The impact of any conversion on the company's share capital and promoter holding.
- Subsequent exchange disclosures regarding implementation timelines.
What to track next
Shareholders should watch for the company's allotment announcement, regulatory filings and any disclosures regarding the timing of warrant conversion. These updates will determine when the approved securities become part of the company's equity capital.